Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현정 | - |
dc.date.accessioned | 2020-05-25T16:30:08Z | - |
dc.date.available | 2020-05-25T16:30:08Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.other | OAK-26965 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/253911 | - |
dc.description.abstract | Antibody drug conjugates (ADCs), consisting of a cancer-specific antibody and cytotoxic payload, are shown to be a potent class of anticancer therapeutics, with enhanced therapeutic efficacy and reduced "off-target" side effects. However, the therapeutic window of ADCs is narrowed by problems such as difficulty in site-specific conjugation of payload, changes in antibody stability due to payload conjugation, and difficulty in tissue penetration. In this respect, aptamers have advantages in drug-delivery, as they can be easily and stably conjugated with cytotoxic drugs. We previously reported that oligobody, an aptamer-antibody complex, is a novel delivery method for aptamer-based therapeutics. In the current study, we describe DOligobody, a drug-conjugated oligobody comprising an aptamer-drug conjugate and an antibody. A cotinine-conjugated anti-HER2 aptamer (cot-HER2apt) was specifically bound to HER2-positive NCI-N87 cells, and underwent receptor-mediated endocytosis. Further, HER2-DOligobody, a cot-HER2apt-conjugated monomethyl auristatin E (cot-HER2apt-MMAE) oligobody, inhibited the growth of HER2-positive NCI-N87 cells. Finally, systemic administration of HER2-DOligobody significantly reduced tumor growth in a xenograft mouse model. Taken together, these results suggest that our DOligobody strategy may be a powerful platform for rapid, low-cost and effective cancer therapy. | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.subject | aptamer | - |
dc.subject | antibody-drug conjugate (ADC) | - |
dc.subject | oligobody | - |
dc.subject | drug-conjugated oligobody (DOligobody) | - |
dc.subject | HER2 | - |
dc.subject | cancer therapeutics | - |
dc.title | Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody) | - |
dc.type | Article | - |
dc.relation.issue | 9 | - |
dc.relation.volume | 21 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.journaltitle | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.identifier.doi | 10.3390/ijms21093286 | - |
dc.identifier.wosid | WOS:000535581700257 | - |
dc.identifier.scopusid | 2-s2.0-85084721715 | - |
dc.author.google | Kim, Hyun Jung | - |
dc.author.google | Sung, Ho Jin | - |
dc.author.google | Lee, Yul Min | - |
dc.author.google | Choi, Sun Il | - |
dc.author.google | Kim, Yun-Hee | - |
dc.author.google | Heo, Kyun | - |
dc.author.google | Kim, In-Hoo | - |
dc.date.modifydate | 20211001081000 | - |